Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Medtronic
Johnson and Johnson
Harvard Business School

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Lucitanib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Lucitanib?

Lucitanib is an investigational drug.

There have been 9 clinical trials for Lucitanib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2019.

The most common disease conditions in clinical trials are Lung Neoplasms, Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are Clovis Oncology, Inc., Bristol-Myers Squibb, and Institut de Recherches Internationales Servier.

There are fifty-eight US patents protecting this investigational drug and four hundred and two international patents.

Recent Clinical Trials for Lucitanib
TitleSponsorPhase
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyClovis Oncology, Inc.Phase 1/Phase 2
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyEli Lilly and CompanyPhase 1/Phase 2
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyExelixisPhase 1/Phase 2

See all Lucitanib clinical trials

Clinical Trial Summary for Lucitanib

Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib

See all Lucitanib clinical trials

US Patents for Lucitanib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lucitanib ⤷  Try it Free Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Try it Free
Lucitanib ⤷  Try it Free Human anti-VEGFR-2/KDR antibodies KADMON CORPORATION, LLC (New York, NY) ⤷  Try it Free
Lucitanib ⤷  Try it Free Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Try it Free
Lucitanib ⤷  Try it Free Gene fusions and gene variants associated with cancer LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA) ⤷  Try it Free
Lucitanib ⤷  Try it Free Rho kinase inhibitors KADMON CORPORATION, LLC (New York, NY) ⤷  Try it Free
Lucitanib ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lucitanib

Drugname Country Document Number Estimated Expiration Related US Patent
Lucitanib World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Try it Free
Lucitanib Canada CA2926386 2032-10-05 ⤷  Try it Free
Lucitanib China CN105007939 2032-10-05 ⤷  Try it Free
Lucitanib China CN109160950 2032-10-05 ⤷  Try it Free
Lucitanib Eurasian Patent Organization EA032679 2032-10-05 ⤷  Try it Free
Lucitanib Eurasian Patent Organization EA201500363 2032-10-05 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Medtronic
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.